These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21558622)

  • 1. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.
    Tran L; Baars JW; de Boer JP; Hoefnagel CA; Beijnen JH; Huitema AD
    Hum Antibodies; 2011; 20(1-2):37-40. PubMed ID: 21558622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis.
    Tran L; Vogel WV; Sinaasappel M; Muller S; Baars JW; van Rijswijk M; Dinant HJ; Beijnen JH; Huitema AD
    Hum Antibodies; 2011; 20(1-2):7-14. PubMed ID: 21558619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.
    Tran L; Huitema AD; van Rijswijk MH; Dinant HJ; Baars JW; Beijnen JH; Vogel WV
    Hum Antibodies; 2011; 20(1-2):29-35. PubMed ID: 21558621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma.
    Scheidhauer K; Wolf I; Baumgartl HJ; Von Schilling C; Schmidt B; Reidel G; Peschel C; Schwaiger M
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1276-82. PubMed ID: 12271407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.
    Tran L; Baars JW; Aarden L; Beijnen JH; Huitema AD
    Hum Antibodies; 2010; 19(1):7-13. PubMed ID: 20555126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma.
    Shen S; Forero A; Meredith RF; Shah JJ; Knox SJ; Wiseman GA; Usrey ME; Lobuglio AF
    J Nucl Med; 2010 Jan; 51(1):150-7. PubMed ID: 20008989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of prospective whole-body bone marrow dosimetry by SPECT/CT multimodality imaging in (131)I-anti-CD20 rituximab radioimmunotherapy of non-Hodgkin's lymphoma.
    Boucek JA; Turner JH
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):458-69. PubMed ID: 15821965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
    de Nully Brown P; Jurlander J; Lindén O; Hansen M
    Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma?
    Leonard JP
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):540-2. PubMed ID: 23073054
    [No Abstract]   [Full Text] [Related]  

  • 12. Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.
    Boucek JA; Turner JH
    Cancer Biother Radiopharm; 2014 Feb; 29(1):18-25. PubMed ID: 24134141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
    Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
    J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy in follicular lymphoma.
    Illidge T; Morschhauser F
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):279-93. PubMed ID: 21658624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study.
    Behr TM; Griesinger F; Riggert J; Gratz S; Béhé M; Kaufmann CC; Wörmann B; Brittinger G; Becker W
    Cancer; 2002 Feb; 94(4 Suppl):1363-72. PubMed ID: 11877767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
    Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
    Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital.
    Turner JH; Martindale AA; Boucek J; Claringbold PG; Leahy MF
    Cancer Biother Radiopharm; 2003 Aug; 18(4):513-24. PubMed ID: 14503945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
    Leahy MF; Seymour JF; Hicks RJ; Turner JH
    J Clin Oncol; 2006 Sep; 24(27):4418-25. PubMed ID: 16940276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
    Yadav MP; Singla S; Thakral P; Ballal S; Bal C
    Nucl Med Commun; 2016 Jul; 37(7):735-42. PubMed ID: 26974315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.